AVTR vs. NBIX: Avantor vs. Neurocrine Biosciences Stock Comparison
How do Avantor (AVTR) and Neurocrine Biosciences (NBIX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Avantor (AVTR) and Neurocrine Biosciences (NBIX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AVTR is classified in Life Sciences Tools & Services while NBIX is classified in Biotechnology.
| Profile Item | AVTR | NBIX |
|---|---|---|
| Name | Avantor, Inc. | Neurocrine Biosciences, Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Biotechnology |
| GICS Sub-Industry | Life Sciences Tools & Services | Biotechnology |
| Market Capitalization | 10.48 billion USD | 16.66 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | May 17, 2019 | May 23, 1996 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AVTR | NBIX |
|---|---|---|
| Total Return (1Y) | 36.41% | 9.40% |
| Total Return (3Y, Annualized) | -5.02% | 14.12% |
| Total Return (5Y, Annualized) | -16.62% | 12.61% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AVTR | NBIX |
|---|---|---|
| Volatility (1Y, Annualized) | 43.39% | 35.05% |
| Beta (5Y) | 0.94 | 0.29 |
| Max Drawdown (5Y) | -82.42% | -42.89% |
| Avg. Volume (3M) | 8.56M | 1.31M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AVTR | NBIX |
|---|---|---|
| Sharpe Ratio (1Y) | 0.74 | 0.15 |
| Sortino Ratio (1Y) | 1.17 | 0.22 |
Profitability
ROE (TTM)
Neurocrine Biosciences (NBIX) at 20.42% sits in the top ROE quartile, while Avantor (AVTR) at 5.91% is closer to the peer norm — stronger capital efficiency for NBIX.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.91%
- Max
- 109.18%
- Q3
- 6.23%
- AVTR
- 5.91%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.42%
- Max
- 109.18%
- NBIX
- 20.42%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Neurocrine Biosciences (NBIX) at 18.98% keeps the most of each sales dollar — above its industry’s net margin range — and Avantor (AVTR) at 5.08% also retains a top-quartile share.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.08%
- Max
- 18.05%
- AVTR
- 5.08%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.98%
- NBIX
- 18.98%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Neurocrine Biosciences (NBIX) at 31.98% operates in the top operating margin quartile, ahead of Avantor (AVTR) at 8.19%, which runs around its industry’s norm.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.19%
- Max
- 83.12%
- Q3
- 14.77%
- AVTR
- 8.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.98%
- Max
- 83.12%
- NBIX
- 31.98%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AVTR | NBIX |
|---|---|---|
| ROE (TTM) | 5.91% | 20.42% |
| ROA (TTM) | 2.83% | 12.45% |
| Net Margin (TTM) | 5.08% | 18.98% |
| Operating Margin (TTM) | 8.19% | 31.98% |
| Gross Margin (TTM) | 31.59% | 64.67% |
Growth
Revenue Growth
Neurocrine Biosciences (NBIX) at 21.45% is around its peer norm for revenue growth, while Avantor (AVTR) at -3.41% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Neurocrine Biosciences (NBIX) at 41.95% is around its peer norm for EPS growth, while Avantor (AVTR) at -175.00% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | AVTR | NBIX |
|---|---|---|
| Revenue Growth (YoY) | -3.41% | 21.45% |
| Revenue Growth (3Y CAGR) | -4.46% | 24.32% |
| EPS Growth (YoY) | -175.00% | 41.95% |
| EPS Growth (3Y CAGR) | -- | 44.12% |
Financial Strength
Current Ratio (MRQ)
Both Avantor (AVTR) at 1.89 and Neurocrine Biosciences (NBIX) at 2.04 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.89
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AVTR
- 1.89
- Min
- 0.10
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.04
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- NBIX
- 2.04
- Min
- 0.10
Debt / Equity (MRQ)
Both Avantor (AVTR) at 0.63 and Neurocrine Biosciences (NBIX) at 0.12 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.63
- Max
- 1.42
- Q3
- 0.65
- AVTR
- 0.63
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.12
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- NBIX
- 0.12
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AVTR | NBIX |
|---|---|---|
| Current Ratio (MRQ) | 1.89 | 2.04 |
| Debt / Equity (MRQ) | 0.63 | 0.12 |
| Net Debt / EBITDA | 3.40 | -0.27 |
Dividends
Dividend Yield (TTM)
Neither Avantor (AVTR) nor Neurocrine Biosciences (NBIX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NBIX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Avantor (AVTR) nor Neurocrine Biosciences (NBIX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NBIX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AVTR | NBIX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Both Avantor (AVTR) at 30.94 and Neurocrine Biosciences (NBIX) at 24.43 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.94
- Max
- 85.34
- Q3
- 43.46
- AVTR
- 30.94
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
24.43
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- NBIX
- 24.43
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Avantor (AVTR) at 1.58 sits in the cheaper P/S ratio quartile while Neurocrine Biosciences (NBIX) at 4.50 prices around its industry’s middle — AVTR costs less per dollar of sales, though read it alongside growth and margins.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.58
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- AVTR
- 1.58
- Min
- 0.01
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.50
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- NBIX
- 4.50
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Avantor (AVTR) at 1.80 and Neurocrine Biosciences (NBIX) at 4.30 are valued close to their industries’ norm against book — neither stands out from peers.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.80
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- AVTR
- 1.80
- Q1
- 1.69
- Min
- -5.59
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.30
- Max
- 13.53
- Q3
- 6.54
- NBIX
- 4.30
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | AVTR | NBIX |
|---|---|---|
| P/E Ratio (TTM) | 30.94 | 24.43 |
| P/S Ratio (TTM) | 1.58 | 4.50 |
| P/B Ratio (MRQ) | 1.80 | 4.30 |
| Free Cash Flow Yield (TTM) | 4.21% | 6.11% |